România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer ireland pharmaceuticals - irlanda - combinatii (gestodenum+etinilestradiolum) - draj. - 0,075mg/0,020mg - contraceptive hormonale sistemice progesteroni si estrogeni combinatii fixe

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer europe ma eeig - combinatii (gestodenum+etinilestradiolum) - draj. - 0,075mg/0,020mg - contraceptive hormonale sistemice progesteroni si estrogeni combinatii fixe

Uniunea Europeană - română - EMA (European Medicines Agency)

mylan ireland limited - acetat de abirateron - prostate neoplasme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Uniunea Europeană - română - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostate neoplasme - terapia endocrină - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostate neoplasme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Uniunea Europeană - română - EMA (European Medicines Agency)

bayer ag - darolutamide - neoplasmele prostatice, rezistent la castrare - terapia endocrină - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

eris pharmaceuticals (australia) pty ltd - cyproteronum - comprimate - 50 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

warner chilcott uk ltd. - testosteron - disfuncții sexuale, psihologice - hormoni sexuali și modulatori ai sistemului genital, - intrinsa este indicat pentru tratamentul hypoactive dorinta sexuala tulburare (hsdd) în bilateral oophorectomised şi hysterectomised (menopauzei induse chirurgical) femei primesc concomitent estrogen terapie.

Uniunea Europeană - română - EMA (European Medicines Agency)

warner chilcott  deutschland gmbh - testosteron - disfuncții sexuale, psihologice - hormoni sexuali și modulatori ai sistemului genital, - livensa este indicat pentru tratamentul hypoactive dorinta sexuala tulburare (hsdd) în bilateral oophorectomised şi hysterectomised (menopauzei induse chirurgical) femei primesc concomitent estrogen terapie.

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - acetat de abirateron - prostate neoplasme - terapia endocrină - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.